Abstract
Type IV collagen is a major component of vascular basement membranes. The noncollagenous (NC1) domains of several α-chains of type IV collagen reveal a capacity to inhibit angiogenesis and tumor growth. Here, we demonstrate that the NC1 domain of the α6 chain of type IV collagen (α6NC1) is an endogenous inhibitor of angiogenesis and tumor growth. Recombinant α6NC1 inhibits human endothelial cell proliferation and neovascularization of Matrigel plugs in mice. The α6NC1 suppresses the growth of subcutaneously transplanted Lewis lung carcinoma and also spontaneous pancreatic insulomas that develop in the Rip1Tag2 mice. Inhibition of tumor growth is associated with significantly diminished microvascular density. Collectively, our results demonstrate that α6NC1 is an endogenous inhibitor of angiogenesis and tumor growth.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1738-1744 |
| Number of pages | 7 |
| Journal | International journal of cancer |
| Volume | 122 |
| Issue number | 8 |
| DOIs | |
| State | Published - Apr 15 2008 |
| Externally published | Yes |
Keywords
- Endogenous angiogenesis inhibitor
- Hexastatin
- NC1 domain
- Noncollagenous
- Tumor
- Type IV collagen
- α6 chain
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Type IV collagen α6 chain-derived noncollagenous domain 1 (α6(IV)NC1) inhibits angiogenesis and tumor growth'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS